Previous close | 10.50 |
Open | 10.50 |
Bid | 6.00 |
Ask | 12.60 |
Strike | 390.00 |
Expiry date | 2025-01-17 |
Day's range | 10.50 - 10.50 |
Contract range | N/A |
Volume | |
Open interest | 123 |
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.
BOSTON, May 22, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences.
While CF remains the main area of focus, Vertex (VRTX) has seen rapid success in its non-CF pipeline candidates' development in the past year.